[S-35] Progressive multifocal leukoencephalopathy in the era of disease-modifying therapies

[S-35-2] A controlled inflammation and a regulatory immune system are associated with better prognosis of PML

Nobuo Sanjo¹, Yukiko Shishido-hara², Yurie Nose¹, Takanori Yokota¹ (1.Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan, 2.Department of Anatomic Pathology, Tokyo Medical University)

Progressive multifocal leukoencephalopathy (PML) is a rare and severe demyelinating disease of the white matter in the central nervous system caused by JC virus. Multiple sclerosis (MS) treating with disease-modifying therapies (DMT) is newly coming underlying disease of PML. In MS, DMT have recently been shown to reduce the frequency and severity of clinical relapse. Although freedom from disease activity has become the primary aim of the treatment of MS, these DMT increase the risk of PML.
In this symposium, latest information of DMT induced PML, characteristics of MRI in DMT induced PML, development of JC virus DNA detection in the cerebrospinal fluid, and newly aspects of PML will be presented.

2016/Aug-present: Professor, Tokyo Medical and Dental University
2016/Apr-Aug: Senior Associate Professor, Tokyo Medical and Dental University
2011/Feb-2016/Mar: Junior Associate Professor, Tokyo Medical and Dental University
2006/Nov-2011/Feb: Assistant Professor, Tokyo Medical and Dental University
2002/Apr-2006/Oct: Post-doctoral fellow, Centre for Research in Neurodegenerative Diseases, University of Toronto